Abstract: Compounds of general formula (I): (I) wherein R1, R2, R3, R4, R5, Y and Z are as defined herein are useful for treating respiratory disease and other diseases and conditions modulated by TMEM16A.

Abstract: Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.

Abstract: An optical system comprising: a sensor array having a field of view; an emitter array comprising a plurality of emitter units mounted on a surface of a common substrate and arranged in a two-dimensional array, wherein each emitter unit in the plurality of emitter units is spaced apart from its adjacent emitter units by a first pitch and emits pulses of light having a predetermined beam divergence; and a fly's eye element spaced apart from the emitter array and configured to spread light received from each emitter unit in the plurality of emitter units element across the entire field of view of the sensor array, the fly's eye element comprising a first and second arrays of lenslets spaced apart from each other, wherein individual lenslets in the first and second arrays of lenslets are spaced apart from each other in at least one dimension by a second pitch that is different than the first pitch, and wherein each individual lenslets in the first array of lenslets is aligned with a corresponding lenslet in the s

Abstract: The present invention relates to methods of treating MYD88-mutant B-cell lymphomas using IRAK4 degrader.

Abstract: The present invention relates to IRAKIMiD degraders, their liquid formulations, and methods of use thereof for treating cancer.

Abstract: Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.

Abstract: Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine.

Abstract: Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.

Abstract: Methods of treating patients diagnosed with cancer harboring an IDH-1 mutation are provided, including the therapeutic administration of a certain inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA).

Abstract: Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine.

Abstract: Methods of treating patients diagnosed with cancer harboring an IDH-1 mutation are provided, including the therapeutic administration of a certain inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA).

Abstract: Payment systems allowing credit and/or points to fund financial transactions are provided. In one example, a payment system comprises a credit device issued to a consumer enabling the consumer to purchase products or services from a plurality of merchants using funds from a credit account associated with the consumer. The payment system comprises a payment network enabling the plurality of merchants to receive payment from an issuer that issues the credit device to the consumer. A funding device is configured to access information regarding credit available from the credit account, the funding device further configured to access information regarding points available to the consumer. The funding device is configured to use pre-established rules to determine the use of available credit and available points for completing a transaction with a first merchant of the plurality of merchants. The transaction appears to the first merchant as a regular credit card transaction.

Abstract: Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.

Abstract: The present invention relates to methods of treating MYD88-mutant B-cell lymphomas using IRAK4 degraders.

Abstract: Payment systems allowing credit and/or points to fund financial transactions are provided. In one example, a payment system comprises a credit device issued to a consumer enabling the consumer to purchase products or services from a plurality of merchants using funds from a credit account associated with the consumer. The payment system comprises a payment network enabling the plurality of merchants to receive payment from an issuer that issues the credit device to the consumer. A funding device is configured to access information regarding credit available from the credit account, the funding device further configured to access information regarding points available to the consumer. The funding device is configured to use pre-established rules to determine the use of available credit and available points for completing a transaction with a first merchant of the plurality of merchants. The transaction appears to the first merchant as a regular credit card transaction.

Abstract: Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.

Abstract: Methods of treating patients diagnosed with cancer harboring an IDH-1 mutation are provided, including the therapeutic administration of a certain inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA).

Abstract: Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine.

Abstract: Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.

Abstract: Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine.